Mumbai, Oct. 10 -- Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate "SON-080" for the treatment of diabetic peripheral neuropathy in India.

Published by HT Digital Content Services with permission from Capital Market....